# Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer

> **NCT00535015** · PHASE2 · TERMINATED · sponsor: **Anaborex** · enrollment: 70 (estimated)

## Conditions studied

- Anorexia
- Cachexia
- Weight Loss
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Betamarc

## Key facts

- **NCT ID:** NCT00535015
- **Lead sponsor:** Anaborex
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2008-06
- **Final completion:** 2008-08
- **Target enrollment:** 70 (ESTIMATED)
- **Why stopped:** Objectives of study could not be met within a reasonable timeframe.
- **Last updated:** 2008-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535015, "Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00535015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*